Brief: Bausch + Lomb Announces Statistically Significant Results From Clinical Study Of Novel Daily Nutritional Supplement
April 25 (Reuters) - Bausch + Lomb Corp BLCO.TO :
* BAUSCH + LOMB ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS
FROM A
CLINICAL STUDY OF A NOVEL DAILY NUTRITIONAL SUPPLEMENT FOR DRY
EYES
* BAUSCH + LOMB CORP: CLINICAL STUDY MET BOTH PRIMARY
ENDPOINTS
* BAUSCH + LOMB CORP: STUDY ALSO MET SECONDARY ENDPOINTS
* BAUSCH + LOMB CORP: NO SERIOUS ADVERSE EVENTS WERE
REPORTED
DURING STUDY PERIOD
* BAUSCH + LOMB CORP: NUTRITEARS WAS FOUND TO BE
WELL-TOLERATED
Source text for Eikon: ID:nBw9J9RH5a
Further company coverage: BLCO.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser